| Trial ID: | L1360 |
| Source ID: | NCT02238977
|
| Associated Drug: |
Fluoxetine
|
| Title: |
Bupropion for Depression in ESRD Patients on Hemodialysis
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02238977/results
|
| Conditions: |
Major Depression|End Stage Renal Disease
|
| Interventions: |
DRUG: Fluoxetine|DRUG: Bupropion
|
| Outcome Measures: |
Primary: Depression Severity, Depression severity as measured by the 25-item Hamilton Depression Rating Scale. The Hamilton Depression Rating Scale has proven useful for determining the level of depression before, during, and after treatment. It is based on the clinician's interview with the patient/participant and probes symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels and weight loss. The rater enters a number for each symptom construct that ranges from 0 (not present) to 4 (extreme symptoms). The higher the total score the more severe the depression. The scale is scored by summing the total of all items. The maximum possible total score is 66 and the minimum is 0. A score \> 17 is considered compatible with a diagnosis of major depression. A score \< 10 is considered clinical remission. The interview and scoring takes about 15 minutes., up to 12 weeks |
|
| Sponsor/Collaborators: |
Sponsor: University of Arkansas | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-03-31
|
| Completion Date: |
2018-03-01
|
| Results First Posted: |
2018-07-17
|
| Last Update Posted: |
2018-07-17
|
| Locations: |
University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02238977
|
